Skip to main content

Articles By John Swoep

Treatment Switch Between a JAK Inhibitor and TNF Inhibitor in Patients with RA

Treatment Switch Between a JAK Inhibitor (upadacitinib) and TNF Inhibitor (adalimumab) in Patients with RA

Sponsored by AbbVie
01 June 2020

What happens when a patient doesn’t adequately respond to a JAK inhibitor or a TNF inhibitor? This video reviews data from the SELECT-COMPARE study looking at what happens when RA patients who have an insufficient response to a JAK inhibitor (upadacitinib) or TNF inhibitor (adalimumab) switch to the alternate therapy.

Read Article
×